Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.
Below is the abstract of the article.
Read the full article PDF by clicking here or on the link below.
In a recent article, Timothy Burns et al. reviewed the incidence of
KRAS mutations in lung cancer, discussing strategies that have not worked in
KRAS-mutated lung cancer. Importantly KRAS
G12C inhibitors are starting to show promise in the clinic and in combination with immunotherapy.
The long undruggable
KRAS mutations driving cancer growth may at last prove to be vulnerable for the therapeutic treatment of lung cancer.
Murali Janakiram, MD, MS, is assistant professor of medicine at the University of Minnesota, Division of Hematology, Oncology, and Transplantation in Minneapolis.